Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03678883 · ClinicalTrials.gov registry record · Phase 2
9-ING-41 in Patients with Advanced Cancers
A Phase 2 study of Cancer and Pancreatic Cancer, sponsored by Actuate Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT03678883: Active Phase 2 study of Cancer and Pancreatic Cancer, sponsored by Actuate Therapeutics.
NCT03678883 is a Phase 2 study of Cancer and Pancreatic Cancer that is active but no longer recruiting, run by Actuate Therapeutics. The registered enrollment target is 350 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03678883, a Phase 2 study of Cancer and Pancreatic Cancer, is active but no longer recruiting, sponsored by Actuate Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Primary Outcome
The standard assessments used to assign a score to any affected organ system as per the NCI CTCAE 4.03 will be conduced at each protocol-specified timepoint.
Conditions Studied
Interventions
- DRUG Lomustine
- DRUG 9-ING-41
- DRUG Gemcitabine - 21 day cycle
- DRUG Doxorubicin.
- DRUG Carboplatin.
Study Locations (20)
Arizona
- Mayo Clinic - Phoenix
- Arizona Oncology Associates - Tucson
- The University of Arizona Cancer Center - Tucson
Florida
- Florida Cancer Specialists - South - Fort Myers
- Miami Cancer Institute - Miami
- Florida Cancer Specialists - North - St. Petersburg
California
- University of California Irvine Health - Orange
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Minnesota
- MetroMetro-Minnesota Community Oncology Research Consortium (MMCORC) - Minneapolis
- Mayo Clinic - Rochester
New Jersey
- Morristown Medical Center - Morristown
- Capital Health Medical Center/ Hopewell - Pennington
Delaware
- Christiana Care Health Services - Newark
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Illinois
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2019-01-04 |
| Est. Completion | 2026-01 |
| Phase | Phase 2 |
What the registry record for NCT03678883 still lists
NCT03678883 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower).
The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Lomustine is the first listed.
NCT03678883 names 20 study sites across 13 states, led by Arizona, Florida, California.
Frequently Asked Questions
What is clinical trial NCT03678883 about?
NCT03678883 is a clinical study titled "9-ING-41 in Patients with Advanced Cancers". GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
What is the current status of trial NCT03678883?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2019-01-04. Estimated completion is 2026-01.
What conditions does trial NCT03678883 study?
This clinical trial studies the following conditions: Cancer, Pancreatic Cancer, Sarcoma, Pancreatic Adenocarcinoma, Neoplasm Metastasis.
What interventions are being tested in trial NCT03678883?
The interventions under investigation include: Lomustine (DRUG), 9-ING-41 (DRUG), Gemcitabine - 21 day cycle (DRUG), Doxorubicin. (DRUG), Carboplatin. (DRUG).
Who is sponsoring clinical trial NCT03678883?
This trial is sponsored by Actuate Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03678883 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03678883's enrollment target sits among peer trials
350 165th of 615 higher than 449 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI